148 related articles for article (PubMed ID: 26573761)
1. MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300.
Hu Y; Li K; Asaduzzaman M; Cuella R; Shi H; Raguz S; Coombes RC; Zhou Y; Yagüe E
Oncol Rep; 2016 Feb; 35(2):1170-8. PubMed ID: 26573761
[TBL] [Abstract][Full Text] [Related]
2. Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
Asaduzzaman M; Constantinou S; Min H; Gallon J; Lin ML; Singh P; Raguz S; Ali S; Shousha S; Coombes RC; Lam EW; Hu Y; Yagüe E
Breast Cancer Res Treat; 2017 Jun; 163(3):461-474. PubMed ID: 28341962
[TBL] [Abstract][Full Text] [Related]
3. The miR-106b~25 cluster promotes bypass of doxorubicin-induced senescence and increase in motility and invasion by targeting the E-cadherin transcriptional activator EP300.
Zhou Y; Hu Y; Yang M; Jat P; Li K; Lombardo Y; Xiong D; Coombes RC; Raguz S; Yagüe E
Cell Death Differ; 2014 Mar; 21(3):462-74. PubMed ID: 24270410
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic EP300 can be targeted with inhibitors of aldo-keto reductases.
Mahmud Z; Asaduzzaman M; Kumar U; Masrour N; Jugov R; Coombes RC; Shousha S; Hu Y; Lam EW; Yagüe E
Biochem Pharmacol; 2019 May; 163():391-403. PubMed ID: 30862505
[TBL] [Abstract][Full Text] [Related]
5. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
6. Biophysical characterization of MDR breast cancer cell lines reveals the cytoplasm is critical in determining drug sensitivity.
Coley HM; Labeed FH; Thomas H; Hughes MP
Biochim Biophys Acta; 2007 Apr; 1770(4):601-8. PubMed ID: 17270349
[TBL] [Abstract][Full Text] [Related]
7. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
Zhu W; Xu H; Zhu D; Zhi H; Wang T; Wang J; Jiang B; Shu Y; Liu P
Cancer Chemother Pharmacol; 2012 Mar; 69(3):723-31. PubMed ID: 21993663
[TBL] [Abstract][Full Text] [Related]
8. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY
Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
Wu DD; Li XS; Meng XN; Yan J; Zong ZH
Tumour Biol; 2016 Aug; 37(8):10499-506. PubMed ID: 26850595
[TBL] [Abstract][Full Text] [Related]
10. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells.
Huang Y; Ibrado AM; Reed JC; Bullock G; Ray S; Tang C; Bhalla K
Leukemia; 1997 Feb; 11(2):253-7. PubMed ID: 9009089
[TBL] [Abstract][Full Text] [Related]
11. miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells.
Takwi AA; Wang YM; Wu J; Michaelis M; Cinatl J; Chen T
Oncogene; 2014 Jul; 33(28):3717-29. PubMed ID: 23934188
[TBL] [Abstract][Full Text] [Related]
12. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
14. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
15. Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation.
Aldonza MB; Hong JY; Alinsug MV; Song J; Lee SK
Oncotarget; 2016 Jun; 7(23):34395-419. PubMed ID: 27284014
[TBL] [Abstract][Full Text] [Related]
16. miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression.
Zou Z; Zou R; Zong D; Shi Y; Chen J; Huang J; Zhu J; Chen L; Bao X; Liu Y; Liu W; Huang W; Hu J; Chen Z; Lao X; Chen C; Huang X; Lu Y; Ni X; Fang D; Wu D; Lu S; Jiang M; Qiu C; Wu Y; Qiu Q; Dong Y; Su Y; Zhao C; Zhong Z; Cai J; Liang Y
J Cell Mol Med; 2017 Sep; 21(9):1929-1943. PubMed ID: 28411377
[TBL] [Abstract][Full Text] [Related]
17. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
[TBL] [Abstract][Full Text] [Related]
18. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
19. Introduction of gadd153 gene into gastric cancer cells can modulate sensitivity to anticancer agents in association with apoptosis.
Kim R; Ohi Y; Inoue H; Aogi K; Toge T
Anticancer Res; 1999; 19(3A):1779-83. PubMed ID: 10470115
[TBL] [Abstract][Full Text] [Related]
20. Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.
Genovese I; Ilari A; Assaraf YG; Fazi F; Colotti G
Drug Resist Updat; 2017 May; 32():23-46. PubMed ID: 29145976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
